$RCKT
ROCKET PHARMACEUTICALS, INC.

2024 Q4 Form 10-Q Financial Statement

#000095017024123459 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $27.11M $18.58M
YoY Change 45.9% 23.01%
% of Gross Profit
Research & Development $42.32M $46.84M
YoY Change -9.67% 7.98%
% of Gross Profit
Depreciation & Amortization $1.900M $1.760M
YoY Change 7.95% 8.64%
% of Gross Profit
Operating Expenses $69.42M $65.43M
YoY Change 6.11% 11.87%
Operating Profit -$69.42M -$65.43M
YoY Change 6.11% 11.87%
Interest Expense $471.0K $469.0K
YoY Change 0.43% 0.86%
% of Operating Profit
Other Income/Expense, Net $1.849M $2.280M
YoY Change -18.9% -1561.54%
Pretax Income -$66.72M -$61.90M
YoY Change 7.79% 7.18%
Income Tax
% Of Pretax Income
Net Earnings -$66.72M -$61.90M
YoY Change 7.79% 7.17%
Net Earnings / Revenue
Basic Earnings Per Share -$0.71 -$0.75
Diluted Earnings Per Share -$0.71 -$0.75
COMMON SHARES
Basic Shares Outstanding 91.16M 90.98M 80.53M
Diluted Shares Outstanding 94.16M 82.64M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $235.7M $437.2M
YoY Change -46.1% 42.63%
Cash & Equivalents $65.60M $225.7M
Short-Term Investments $170.1M $211.5M
Other Short-Term Assets $6.092M $9.700M
YoY Change -37.2% 111.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $241.8M $446.9M
YoY Change -45.9% 43.63%
LONG-TERM ASSETS
Property, Plant & Equipment $38.51M $36.53M
YoY Change 5.42% 42.64%
Goodwill $39.20M $39.20M
YoY Change 0.0% 27.21%
Intangibles $25.15M $25.15M
YoY Change 0.0%
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $1.865M $1.900M
YoY Change -1.84% 5.03%
Total Long-Term Assets $151.9M $151.9M
YoY Change 0.02% 43.12%
TOTAL ASSETS
Total Short-Term Assets $241.8M $446.9M
Total Long-Term Assets $151.9M $151.9M
Total Assets $393.7M $598.8M
YoY Change -34.25% 43.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $35.37M $29.90M
YoY Change 18.29% 12.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.842M $1.800M
YoY Change 2.33% 4.41%
Total Short-Term Liabilities $39.98M $33.48M
YoY Change 19.43% 10.92%
LONG-TERM LIABILITIES
Long-Term Debt $19.38M $19.30M
YoY Change 0.42% 0.3%
Other Long-Term Liabilities $1.142M $1.869M
YoY Change -38.9% 4951.35%
Total Long-Term Liabilities $1.142M $1.869M
YoY Change -38.9% 4951.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.98M $33.48M
Total Long-Term Liabilities $1.142M $1.869M
Total Liabilities $63.92M $57.68M
YoY Change 10.82% 15.46%
SHAREHOLDERS EQUITY
Retained Earnings -$1.160B -$899.7M
YoY Change 28.93% 39.04%
Common Stock $911.0K $901.0K
YoY Change 1.11% 32.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $329.8M $541.1M
YoY Change
Total Liabilities & Shareholders Equity $393.7M $598.8M
YoY Change -34.25% 43.5%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$66.72M -$61.90M
YoY Change 7.79% 7.17%
Depreciation, Depletion And Amortization $1.900M $1.760M
YoY Change 7.95% 8.64%
Cash From Operating Activities -$52.10M -$57.15M
YoY Change -8.83% 30.3%
INVESTING ACTIVITIES
Capital Expenditures $1.588M $4.660M
YoY Change -65.92% -1026.44%
Acquisitions
YoY Change
Other Investing Activities $80.51M $52.90M
YoY Change 52.19% 120.71%
Cash From Investing Activities $78.92M $48.26M
YoY Change 63.53% 105.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 176.0K 189.5M
YoY Change -99.91% 541.74%
NET CHANGE
Cash From Operating Activities -52.10M -57.15M
Cash From Investing Activities 78.92M 48.26M
Cash From Financing Activities 176.0K 189.5M
Net Change In Cash 26.99M 180.6M
YoY Change -85.05% 1877.55%
FREE CASH FLOW
Cash From Operating Activities -$52.10M -$57.15M
Capital Expenditures $1.588M $4.660M
Free Cash Flow -$53.69M -$61.81M
YoY Change -13.14% 42.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of R&amp;D expenses, and the valuation of equity transactions and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65599000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55904000
CY2024Q3 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1362000
CY2023Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1372000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66961000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57276000
CY2024Q3 rckt Debt Securities Available For Sale Allowance For Credit Loss Unrealized Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLossUnrealizedLoss
0
CY2023Q3 rckt Debt Securities Available For Sale Allowance For Credit Loss Unrealized Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLossUnrealizedLoss
0
rckt Debt Securities Available For Sale Allowance For Credit Loss Unrealized Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLossUnrealizedLoss
0
rckt Debt Securities Available For Sale Allowance For Credit Loss Unrealized Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLossUnrealizedLoss
0
CY2024Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
400000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-100000
CY2023Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
200000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-200000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
57945000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53204000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19431000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14032000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38514000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39172000
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1900000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5400000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1200000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3500000
dei Entity Central Index Key
EntityCentralIndexKey
0001281895
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36829
dei Entity Registrant Name
EntityRegistrantName
Rocket Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3475813
dei Entity Address Address Line1
EntityAddressAddressLine1
9 Cedarbrook Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Cranbury
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08512
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
659-8001
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
RCKT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91157085
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65599000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55904000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
170063000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
317271000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6092000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5047000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
241754000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
378222000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38514000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39172000
CY2024Q3 us-gaap Goodwill
Goodwill
39154000
CY2023Q4 us-gaap Goodwill
Goodwill
39154000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25150000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25150000
CY2024Q3 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1362000
CY2023Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1372000
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
503000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
533000
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
0
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
34320000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4349000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3901000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
42902000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
44517000
CY2024Q3 us-gaap Assets
Assets
393688000
CY2023Q4 us-gaap Assets
Assets
566341000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
37133000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
45789000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1005000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
925000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1842000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1791000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39980000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
48505000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3413000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2973000
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19382000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19353000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1142000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2936000
CY2024Q3 us-gaap Liabilities
Liabilities
63917000
CY2023Q4 us-gaap Liabilities
Liabilities
73767000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91116692
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91116692
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90282267
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90282267
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
911000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
903000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1486436000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1450722000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
213000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
319000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1157789000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-959370000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
329771000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
492574000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
393688000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
566341000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42315000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46844000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
133887000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
144598000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27109000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18585000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
76624000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51782000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
69424000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
65429000
us-gaap Operating Expenses
OperatingExpenses
210511000
us-gaap Operating Expenses
OperatingExpenses
196380000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-69424000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-65429000
us-gaap Operating Income Loss
OperatingIncomeLoss
-210511000
us-gaap Operating Income Loss
OperatingIncomeLoss
-196380000
CY2024Q3 us-gaap Interest Expense
InterestExpense
471000
CY2023Q3 us-gaap Interest Expense
InterestExpense
469000
us-gaap Interest Expense
InterestExpense
1413000
us-gaap Interest Expense
InterestExpense
1405000
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1327000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1720000
us-gaap Interest And Other Income
InterestAndOtherIncome
6650000
us-gaap Interest And Other Income
InterestAndOtherIncome
4474000
CY2024Q3 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1849000
CY2023Q3 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2279000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6855000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7376000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-66719000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-61899000
us-gaap Net Income Loss
NetIncomeLoss
-198419000
us-gaap Net Income Loss
NetIncomeLoss
-185935000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.3
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94158491
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94158491
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82636120
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82636120
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93893729
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93893729
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80865658
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80865658
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-66719000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-61899000
us-gaap Net Income Loss
NetIncomeLoss
-198419000
us-gaap Net Income Loss
NetIncomeLoss
-185935000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
431000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
216000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-106000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-151000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66288000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61683000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-198525000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-186086000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
492574000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1184000
CY2024Q1 rckt Oci Investments Unrealized Holding Gain Loss Before Adjustment After Tax
OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
-454000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10252000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-62054000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
441502000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1530000
CY2024Q2 rckt Oci Investments Unrealized Holding Gain Loss Before Adjustment After Tax
OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
-83000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11332000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-69646000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
384635000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
176000
CY2024Q3 rckt Oci Investments Unrealized Holding Gain Loss Before Adjustment After Tax
OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
431000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11248000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-66719000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
329771000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
489686000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1114000
CY2023Q1 rckt Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
7000
CY2023Q1 rckt Stock Issued During Period Value At The Market Offering Programs
StockIssuedDuringPeriodValueAtTheMarketOfferingPrograms
17222000
CY2023Q1 rckt Oci Investments Unrealized Holding Gain Loss Before Adjustment After Tax
OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
267000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8915000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-58335000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
458876000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
182000
CY2023Q2 rckt Oci Investments Unrealized Holding Gain Loss Before Adjustment After Tax
OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
-632000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10245000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-65701000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
402970000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
188884000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
545000
CY2023Q3 rckt Oci Investments Unrealized Holding Gain Loss Before Adjustment After Tax
OCIInvestmentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax
214000
CY2023Q3 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
56000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10316000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-61899000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
541086000
us-gaap Net Income Loss
NetIncomeLoss
-198419000
us-gaap Net Income Loss
NetIncomeLoss
-185935000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
5399000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
3548000
rckt Adjustment Of Right Of Use Assets
AdjustmentOfRightOfUseAssets
1615000
rckt Adjustment Of Right Of Use Assets
AdjustmentOfRightOfUseAssets
1615000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
574000
rckt Property Plant And Equipment Write Down
PropertyPlantAndEquipmentWriteDown
0
rckt Property Plant And Equipment Write Down
PropertyPlantAndEquipmentWriteDown
291000
us-gaap Share Based Compensation
ShareBasedCompensation
32832000
us-gaap Share Based Compensation
ShareBasedCompensation
29476000
rckt Accretion Amortization Of Discounts And Premiums Excluding Accretion Income Related To Cash Equivalents Investments
AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments
6845000
rckt Accretion Amortization Of Discounts And Premiums Excluding Accretion Income Related To Cash Equivalents Investments
AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments
7076000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1015000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1962000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5293000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5611000
rckt Increase Decrease In Operating Lease Liability And Right Of Use Assets Net
IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet
72000
rckt Increase Decrease In Operating Lease Liability And Right Of Use Assets Net
IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAssetsNet
120000
rckt Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
80000
rckt Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
109000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1794000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-726000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-162782000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-165577000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
121841000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
182418000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
296971000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
236982000
rckt Payments To Acquire Right Of Use Asset
PaymentsToAcquireRightOfUseAsset
0
rckt Payments To Acquire Right Of Use Asset
PaymentsToAcquireRightOfUseAsset
36000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5553000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11789000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
169577000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42739000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2890000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1841000
us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
0
us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
56000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2890000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
208010000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
9685000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
85172000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57276000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
141857000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66961000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
227029000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
265000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1670000
rckt Non Cash Operating Lease Liability
NonCashOperatingLeaseLiability
1134000
rckt Non Cash Operating Lease Liability
NonCashOperatingLeaseLiability
2813000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-106000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-151000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1160000000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
235700000
CY2024Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
25150000
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
25150000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25150000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
25150000
CY2024Q3 us-gaap Goodwill
Goodwill
39200000
CY2023Q4 us-gaap Goodwill
Goodwill
39200000
CY2024Q3 rckt Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
19074000
CY2023Q4 rckt Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
13867000
CY2024Q3 rckt Investment Payable Current
InvestmentPayableCurrent
0
CY2023Q4 rckt Investment Payable Current
InvestmentPayableCurrent
13137000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10316000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9930000
CY2024Q3 rckt Property And Equipment Payable Current
PropertyAndEquipmentPayableCurrent
265000
CY2023Q4 rckt Property And Equipment Payable Current
PropertyAndEquipmentPayableCurrent
1077000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4708000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6006000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2770000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1772000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
37133000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
45789000
CY2023Q4 rckt Investment Payable Current
InvestmentPayableCurrent
13100000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11248000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10316000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32832000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29476000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11248000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10316000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32832000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29476000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5715078
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66719000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-61899000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-198419000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-185935000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94158491
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94158491
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82636120
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82636120
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
93893729
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93893729
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80865658
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80865658
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.3
CY2024Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2588123
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2588123
CY2023Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2588123
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2588123
CY2024Q3 rckt Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units Exercisable For Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares
1565444
rckt Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units Exercisable For Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares
1565444
CY2023Q3 rckt Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units Exercisable For Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares
1606104
rckt Incremental Common Shares Attributable To Dilutive Effect Of Restricted Stock Units Exercisable For Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnitsExercisableForCommonShares
1606104
CY2024Q3 rckt Incremental Common Shares Attributable To Dilutive Effect Of Performance Stock Units Exercisable For Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares
121907
rckt Incremental Common Shares Attributable To Dilutive Effect Of Performance Stock Units Exercisable For Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares
121907
CY2023Q3 rckt Incremental Common Shares Attributable To Dilutive Effect Of Performance Stock Units Exercisable For Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares
0
rckt Incremental Common Shares Attributable To Dilutive Effect Of Performance Stock Units Exercisable For Common Shares
IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceStockUnitsExercisableForCommonShares
0
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
16148020
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
16148020
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14889669
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14889669
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20423494
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20423494
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19083896
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19083896
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-10-31
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
200000
CY2024Q3 us-gaap Direct Costs Of Leased And Rented Property Or Equipment
DirectCostsOfLeasedAndRentedPropertyOrEquipment
600000
us-gaap Direct Costs Of Leased And Rented Property Or Equipment
DirectCostsOfLeasedAndRentedPropertyOrEquipment
2000000
CY2023Q3 us-gaap Direct Costs Of Leased And Rented Property Or Equipment
DirectCostsOfLeasedAndRentedPropertyOrEquipment
700000
us-gaap Direct Costs Of Leased And Rented Property Or Equipment
DirectCostsOfLeasedAndRentedPropertyOrEquipment
1700000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
1000000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
1000000
us-gaap Operating Lease Cost
OperatingLeaseCost
956000
us-gaap Operating Lease Cost
OperatingLeaseCost
1026000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1615000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1615000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1413000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1405000
us-gaap Lease Cost
LeaseCost
3984000
us-gaap Lease Cost
LeaseCost
4046000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
257000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1001000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1005000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
759000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
522000
CY2024Q3 rckt Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2420000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5964000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1546000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4418000
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
457000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1856000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
1911000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
1969000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
2028000
CY2024Q3 rckt Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
41003000
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
49224000
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
28000000
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
21224000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4349000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3901000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1005000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
925000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3413000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2973000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4418000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3898000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
42902000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
44517000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1842000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1791000
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19382000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
19353000
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
21224000
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
21144000
us-gaap Operating Lease Payments
OperatingLeasePayments
829000
us-gaap Operating Lease Payments
OperatingLeasePayments
894000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1333000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1296000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P19Y10M24D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P20Y10M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0882
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0834
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0896
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0896
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2000.000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2024Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1300000
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-123459-index-headers.html Edgar Link pending
0000950170-24-123459-index.html Edgar Link pending
0000950170-24-123459.txt Edgar Link pending
0000950170-24-123459-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img173865017_0.jpg Edgar Link pending
img173865017_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rckt-20240930.htm Edgar Link pending
rckt-20240930.xsd Edgar Link pending
rckt-ex31_1.htm Edgar Link pending
rckt-ex31_2.htm Edgar Link pending
rckt-ex32_1.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rckt-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable